Coherus BioSciences (CHRS) Announces CHS-1701 Met Primary PD Endpoints in PK/PD Study; Some Data Still Under Review
Tweet Send to a Friend
Coherus BioSciences (NASDAQ: CHRS) reported the results from its pharmacokinetic and pharmacodynamic (PK/PD) clinical study of CHS-1701, a pegfilgrastim (Neulasta®) ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
